Portal de investigación
- Inicio
- Proyectos y Estudios
- ESTUDIO CLÍNICO, EN FASE III, DE SERIE DE CASOS DE LA REVERSIÓN DE LOS EFECTOS ANTICOAGULANTES DE DABIGATRÁN MEDIANTE ADMINISTRACIÓN INTRAVENOSA DE 5,0 G DE IDARUCIZUMAB (BI 655075) EN PACIENTES TRATADOS CON DABIGATRÁN ETEXILATO QUE TIENEN UNA HEMORRAGIA NO CONTROLADA O REQUIEREN OPERACIÓN QUIRÚRGICA O PROCEDIMIENTO INTERVENCIONISTA URGENTE.
ESTUDIO CLÍNICO, EN FASE III, DE SERIE DE CASOS DE LA REVERSIÓN DE LOS EFECTOS ANTICOAGULANTES DE DABIGATRÁN MEDIANTE ADMINISTRACIÓN INTRAVENOSA DE 5,0 G DE IDARUCIZUMAB (BI 655075) EN PACIENTES TRATADOS CON DABIGATRÁN ETEXILATO QUE TIENEN UNA HEMORRAGIA NO CONTROLADA O REQUIEREN OPERACIÓN QUIRÚRGICA O PROCEDIMIENTO INTERVENCIONISTA URGENTE.
Datos básicos
- Código:
- 1321.3
- Protocolo:
- 1321.3
- EUDRACT:
- 2013-004813-41
- NCT:
- Centro:
- Dotación:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry
Van den Berg, M; (...); Ljung, R
Meeting Abstract. 10.1182/blood-2018-99-114518. 2018
A MODIFICATION OF CALIBRATED AUTOMATED THROMBIN GENERATION ASSAY TO EXPLORE NEW COFACTORS OF ACTIVATED PROTEIN C IN PLASMA
Martos, L.; (...); Navarro Rosales, S.
Meeting Abstract. 10.1016/S0049-3848(14)50233-2. 2014
A post hoc comparative real-world analysis of HEAD-US score for joint health assessment of patients with severe haemophilia A and B in Spain
Alvarez-Roman, Maria Teresa; (...); Kim, Hae Kyung
Article. 10.1111/hae.14924. 2024
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
Peyvandi F; (...); Rosendaal FR
Article. 10.1056/NEJMoa1516437. 2016
A simplified assay for the quantification of circulating activated protein C
Martos L; (...); Medina P
Article. 10.1016/j.cca.2016.05.025. 2016
a2-Macroglobulin is a significant in vivo inhibitor of activated protein C and low levels of APC:a2M are associated with venous thromboembolism
Navarro S; (...); Medina P
Article. 2018
ACUTE MYELOID LEUKEMIA IN PATIENTS 70 AND ABOVE. AZACITIDINE VERSUS INTENSIVE CHEMOTHERAPY
De La Fuente, A.; (...); Ramos, F.
Meeting Abstract. 2014
Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A
García-Dasí M; (...); García-Talavera JA
Article. 10.1111/hae.12618. 2015
Adherence to prophylaxis in adult patients with severe haemophilia A
Bonanad, S; (...); Alvarez, M
Meeting Abstract. 2019
Adherence to prophylaxis in adult patients with severe haemophilia A
Bonanad, S; (...); Alvarez, MP
Article. 10.1111/hae.14039. 2020
Adverse effects after a single moderate-volume strong-intensity strength training session in patients with severe hemophilia: feasibility and safety study
Querol-Fuentes, F; (...); Bonanad, S
Meeting Abstract. 2018
alpha(2)-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC: alpha M-2 Levels Are Associated with Venous Thromboembolism
Martos, L; (...); Medina, P
Article. 10.1055/s-0038-1629902. 2018
Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia.
Article. 10.1002/ccr3.1206. 2017
Analysis of 65 pregnancies in 34 women with five different forms of inherited platelet function disorders
Civaschi E; (...); European Haematology Association - Scientific Working Group on Thrombocytopenias
Article. 10.1111/bjh.13458. 2015
ANALYSIS OF THE USE OF MOBILE APPLICATIONS IN PATIENTS WITH HAEMOPHILIA AFTER TWO YEARS OF FOLLOW-UP
Megias Vericat, J. E.; (...); Bonanad Boix, S.
Meeting Abstract. 2019
Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study.
Paciullo F; (...); Gresele P
Article. 10.3324/haematol.2019.227876. 2020
Assessment of Kinect V2 for elbow range of motion estimation in people with haemophilia using an angle correction model
Mateo, F; (...); Perez-Alenda, S
Article. 10.1111/hae.13744. 2019
Association of Vitamin K and Non-Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients
Iftimi AA; (...); Sanfélix-Gimeno G
Article. 10.1002/cpt.2362. 2021
Azacitidine in older patients with acute myeloid leukemia (AML). Results from the ALMA study according to the MRC risk index score.
Falantes, Jose F.; (...); Ramos, Fernando
Meeting Abstract. 2015
Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy
Querol, Felipe; (...); Bonanad Boix, Santiago
Meeting Abstract. 10.1182/blood-2019-125651. 2019
Benefits of physical activity self-monitoring in patients with haemophilia: a prospective study with one-year follow-up.
Pérez-Alenda S; (...); Núñez-Cortés R
Article. 10.1111/hae.14988. 2024
Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro.
Article. 10.3389/fimmu.2023.1171065. 2023
Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades
Nijdam A; (...); PedNet and CANAL study groups
Letter. 10.3324/haematol.2014.115709. 2015
Bleeding risk of surgery and its prevention in patients with inherited platelet disorders
Orsini, S; (...); European Hematology Association - Scientific Working Group (EHA-SWG) on thromboc
Article. 10.3324/haematol.2016.160754. 2017
Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A.
Tiede A; (...); Persson P
Article. 10.1055/s-0039-3400745. 2020
Case-Control Pilot Study of the Immune Modulating Effect of FEIBA (R) on Patients with Haemophilia a and Inhibitors
Fernandez Bello, Ihosvany; (...); Butta, Nora
Meeting Abstract. 2015
Cerebral calcium embolism.
Asensi Canto, Pedro; (...); Bonanad Boix, Santiago
Article. 10.1002/ccr3.4962. 2022
Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen.
Moret, A; (...); Bonanad, S
Letter. 10.1016/j.thromres.2019.06.015. 2019
CLINICAL AND MOLECULAR CHARACTERIZATION BY SEQUENCING OF NEW GENERATION OF PATIENTS AFFECTED BY FIBRINOGEN CONGENITAL DEFICIENCIES
Moret, A.; (...); Bonanad, S.
Meeting Abstract. 2019
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
Almeida AM; (...); Pleyer L
Article. 10.3390/ijms18040837. 2017
CLINICAL OUTCOMES OF ACUTE ERYTHROLEUKEMIA TREATED WITH AZACITIDINE: A RETROSPECTIVE MULTICENTER STUDY
Almeida, A.; (...); Pleyer, L.
Meeting Abstract. 2015
CLINICAL VALIDATION OF THE SPECIFIC POPULATION MODEL OF FACTOR VIII/FVW PLASMA USING WAPPS-HEMO
Megias Vericat, J. E.; (...); Poveda, A. J. L.
Meeting Abstract. 2019
Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain.
Rodríguez López M; (...); Bonanad S
Article. 10.1136/bcr-2019-234142. 2020
Collaborative model of home delivery program in haemophilia through an association of patients
Megias-Vericat, JE; (...); Bonanad, S
Meeting Abstract. 2018
COMBINED DEFICIENCY OF PROTEIN C, PROTEIN S AND ANTITHROMBIN IN PATIENTS WITH MESENTERIC OR PORTAL VENOUS THROMBOSIS WITH OR WITHOUT HEPATIC CIRRHOSIS
Martos, L.; (...); Espana, F.
Meeting Abstract. 10.1016/S0049-3848(14)50197-1. 2014
Comorbidities in Patients With Hemophilia: Changes in Joints and its Correlation with Bone Mineral Density
Perez-Alenda, S.; (...); Querol, F.
Meeting Abstract. 2015
Comparative analysis of Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) scores in persons with nonsevere hemophilia A and B reveals a high degree of joint damage in both disease types
Jimenez-Yuste, Victor; (...); Kim, Hae Kyung
Letter. 10.1016/j.rpth.2023.102207. 2023
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
COMPREHENSIVE LONG-TERM FOLLOW-UP OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A REPORT FROM A SINGLE CENTRE
Sempere, A.; (...); Jarque, I.
Meeting Abstract. 2016
Comprehensive Screening of Genetic Variants in the Coding Region of F8 in Severe Hemophilia A Reveals a Relationship with Disease Severity in a Colombian Cohort.
Sarmiento Doncel, Samuel; (...); Lopez Guerrero, Jose A
Article. 10.3390/life14081041. 2024
Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation.
Montalvá E; (...); Colmenero J
Article. 10.1097/TP.0000000000004014. 2022
Considering Bone Marrow Blasts from Nonerythroid Cells Improves the Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts
Arenillas, Leonor; (...); Florensa, Lourdes
Meeting Abstract. 2016
Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category
Calvo, Xavier; (...); Florensa, Lourdes
Meeting Abstract. 10.1182/blood.V128.22.3185.3185. 2016
Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes
Arenillas L; (...); Florensa L
Article. 10.1200/JCO.2016.66.9705. 2016
Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients.
Chelle P; (...); Edginton A
Article. 10.1007/s10928-019-09647-2. 2019
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
Challenges, questions and opportunities with regard to the new relationship between clinical practice and the haemostasis laboratory: the path towards personalized medicine.
Article. 10.1097/MBC.0000000000001091. 2021
Delving into the clinical impact of NETs in pediatric cancer.
Benavent N; (...); Medina P
Article. 10.1038/s41390-024-03437-4. 2024
Demographic and baseline data from patients with hemophilia and inhibitors enrolled in the feiba global outcomes ("FEIBA GO") study
Windyga, J; (...); Escuriola-Ettingshausen, C
Meeting Abstract. 2019
DESCRIPTIVE STUDY OF THE RECORD OF THROMBOTIC MICROANGIOPATHY IN A SINGLE CENTRE
Romero Dominguez, S.; (...); Sanz Alonso, M. A.
Meeting Abstract. 2015
DESCRIPTIVE STUDY ON HAEMOPHILIA EXPERIENCE ACQUIRED IN A REFERENCE CENTRE
De la Puerta, R.; (...); Haya Guaita, S.
Meeting Abstract. 2019
Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU.
Fischer K; (...); Königs C
Article. 10.1182/bloodadvances.2023011442. 2024
Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale
Bonanad S; (...); GAH Group
Article. 10.1016/j.jgo.2015.03.003. 2015
Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.
Megias-Vericat, J E; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2024.109122. 2024
Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate ): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup.
Chelle P; (...); Iorio A
Article. 10.1007/s40262-019-00809-6. 2020
DIAGNOSIS AND MANAGEMENT OF HEMARTHROSIS AND HAEMOPHILIC ARTHROPATHY USING UNIFIED CLINICAL AND ULTRASOUND CRITERIA: PRELIMINARY RESULTS
Chimeno-Hernandez, A; (...); Querol, F
Meeting Abstract. 2021
DIAGNOSIS OF JOINT BLEEDS: PREDICTIVE MODELING BASED ON PATIENT-REPORTED SYMPTOMS
Goldmann, G.; (...); Tiede, A.
Meeting Abstract. 2023
DIFFERENT CLINICAL MANIFESTATION OF DYSFIBRINOGENEMIAS ASSOCIATED TO THE MUTATION ARG275 IN EXON 8 OF FGG GENE
Mesa, E.; (...); Bonanad, S.
Meeting Abstract. 10.1016/S0049-3848(14)50268-X. 2014
Effect of monitoring daily physical activity on quality of life in adult patients with haemophilic arthropathy
Perez-Alenda, Sofia; (...); Carrasco, Juan J.
Meeting Abstract. 2018
Effect of Prophylaxis with Activated Prothrombin Complex Concentrate on Anamnestic Response of Patients with Severe Haemophilia A and Inhibitors
Fernandez-Bello, I.; (...); Jimenez-Yuste, V.
Meeting Abstract. 2016
Effect of radiosynoviorthesis on the progression of arthropathy and haemarthrosis reduction in haemophilic patients
Querol-Giner, M.; (...); Querol, F.
Article. 10.1111/hae.13326. 2017
Effective and Safe Management of Oral Anticoagulation Therapy in Patients Who Use the Internet-Accessed Telecontrol Tool SintromacWeb.
Ferrando F, Mira Y
Article. 10.2196/ijmr.3610. 2015
Effectiveness of progressive moderate-vigorous intensity elastic resistance training on quality of life and perceived functional abilities in people with haemophilia: secondary analysis of a randomized controlled trial.
Cruz-Montecinos C; (...); Calatayud J
Article. 10.1111/ejh.13900. 2022
Effects of a non-pharmacological approach for chronic pain management in patients with haemophilia: efficacy of cognitive-behavioural therapy associated with physiotherapy.
García-Dasí M; (...); Bonanad S
Article. 10.1111/hae.14284. 2021
EFFECTS OF MULTIMODAL EXERCISES PROGRAM ON BALANCE, FUNCTIONALITY, RISK OF FALLS AND STRENGTH IN PEOPLE WITH HAEMOPHILIA
Chimeno-Hernandez, A.; (...); Querol, F.
Article. 2022
Efficacy and safety evaluation of Fanhdi ® , a plasma-derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study.
Jimenez-Yuste, Victor; (...); Paez, Antonio
Letter. 10.1111/hae.14453. 2022
EFFICACY AND SAFETY OF EPTACOG BETA (RECOMBINANT HUMAN FVIIA) ACCORDING TO AGE IN PERSONS WITH HAEMOPHILIA A/B WITH INHIBITORS UNDERGOING SURGICAL PROCEDURES
Miesbach, W.; (...); Mahlangu, J.
Meeting Abstract. 2023
eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Megias-Vericat, JE
Meeting Abstract. 2018
Electromyographic and Safety Comparisons of Common Lower Limb Rehabilitation Exercises for People With Hemophilia.
Calatayud J; (...); Casaña J
Article. 10.1093/ptj/pzz146. 2020
Emicizumab-induced photosensitivity.
Asensi Canto, Pedro; (...); Haya Guaita, Saturnino
Article. 10.1055/s-0042-1749092. 2022
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)
Calvo, X; (...); Florensa, L
Article. 10.1002/ajh.24732. 2017
EPTACOG BETA EFFICACY AT 24 HOURS POSTINFUSION FOR MILD OR MODERATE BLEEDS IN INDIVIDUALS WITH HEMOPHILIA A OR B AND INHIBITORS
Boggio, Lisa; (...); Escobar, Miguel
Meeting Abstract. 2023
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes
Calvo X; (...); Florensa L
Article. 10.1038/modpathol.2016.146. 2016
EVALUATION OF ISTH-BAT IN CONGENITAL PLATELET DISORDERS: CLINICAL, LABORATORY AND MOLECULAR CORRELATION
Bastida, J. M.; (...); Rivera, J.
Meeting Abstract. 2019
Evaluation of the effect on endogenous factor VIII activity (FVIII: C) after recombinant von Willebrand factor (rVWF) administration during the elective surgery study in patients with severe von Willebrand disease (VWD)
Mamaev, A; (...); Peyvandi, F
Meeting Abstract. 2018
Experience of Home Delivery Program in Haemophilia Through an Association of Patients
Megias Vericat, J. E.; (...); Bonanad Boix, S.
Meeting Abstract. 2017
Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management.
Moret A; (...); Bonanad S
Article. 10.1007/s11239-020-02065-z. 2020
Feasibility, safety and muscle activity during flywheel vs traditional strength training in adult patients with severe haemophilia.
Calatayud J; (...); Casaña J
Article. 10.1111/hae.14170. 2020
FEIBA GLOBAL OUTCOME (FEIBA GO) STUDY: REAL-WORLD DATA IN PATIENTS WITH CONGENITAL HEMOPHILIA AND INHIBITORS
Hermans, C; (...); Windyga, J
Meeting Abstract. 2021
FEIBA GO STUDY: REAL-WORLD BLEEDING FREQUENCY IN INHIBITOR PATIENTS ON PROPHYLAXIS WITH ACTIVATED PROTHROMBIN COMPLEX CONCENTRATES
Ettingshausen, CE; (...); Crea, R
Meeting Abstract. 2018
FUNCTIONAL ANALYSIS OF TWO HAPLOTYPES OF THE HUMAN ENDOTHELIAL PROTEIN C RECEPTOR GENE (PROCR)
Bonet, E.; (...); Navarro Rosales, S.
Meeting Abstract. 10.1016/S0049-3848(14)50053-9. 2014
Functional and molecular characterization of inherited platelet disorders in the Iberian Peninsula: results from a collaborative study
Sánchez-Guiu I; (...); Lozano ML
Article. 10.1186/s13023-014-0213-6. 2014
Further psychometric validation of the GAH scale: Responsiveness and effect size
Cruz-Jentoft, AJ; (...); GAH Group
Article. 10.1016/j.jgo.2016.12.008. 2017
GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (> 65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES
Bonanad, S; (...); de la Rubia, J
Meeting Abstract. 2017
Gait analysis by means of accelerometry in patients with haemophilic arthropathy
Carrasco, Juan J.; (...); Querol, Felipe
Meeting Abstract. 2016
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; (...); Bonanad, Santiago
Article. 10.1016/j.jgo.2022.10.016. 2022
Haemophilic arthropathy: basic protocols for clinical examination and imaging.
Querol, F.; (...); Perez-Alenda, S.
Article. 10.1097/MBC.0000000000001215. 2023
HaemoPREF: Further evaluation of patient perception and preference for treatment in a real world setting
Bonanad, S; (...); Brohan, E
Article. 10.1111/hae.13321. 2017
Haemotrack: Musculoskeletal management in haemophilia with physiotherapist-driven digital solutions
Perez-Alenda, Sofia; (...); Aguilar-Rodriguez, Marta
Meeting Abstract. 2024
HemoKinect: A Microsoft Kinect V2 Based Exergaming Software to Supervise Physical Exercise of Patients with Hemophilia
Mateo, F; (...); Perez-Alenda, S
Article. 10.3390/s18082439. 2018
HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY
Bastida Bermejo, J. M.; (...); Diez-Campelo, M.
Meeting Abstract. 2016
HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY
Lopez Godino, O.; (...); Diez Campelo, M.
Meeting Abstract. 2015
HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY
Lopez-Godino, O.; (...); Diez Campelo, M.
Meeting Abstract. 10.1016/S0145-2126(15)30309-X. 2015
Home-delivered ultrasound monitoring for home treatment of haemarthrosis in haemophilia A
Letter. 10.1111/hae.12622. 2015
HYPERPROTEIEMIA AND HYPERFIBRINOLYSIS INCREASED IN PREANESHTESIA STUDY
Guinot Segarra, M.; (...); Luch Garcia, R.
Meeting Abstract. 2019
Identification and validation of plasma micrornas involved in venous and arterial thrombosis
Ramon, L. A.; (...); Navarro, S.
Meeting Abstract. 2015
IDENTIFICATION OF 58 MUTATIONS (26 NEW) IN 94 OF 109 BEING TESTED WITH PROTEIN DEFICIENCY C. SETH WORKING GROUP
Fernandez-Pardo, A.; (...); Navarro, S.
Meeting Abstract. 2019
Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency
Martos, L; (...); Spanish Soc Thrombosis Haemostasis
Article. 10.1055/s-0039-1692440. 2019
IDENTIFICATION OF 6 MUTATIONS IN THE PROTEIN C GENE (PROC) IN A PANEL OF 83 SPANISH FAMILIES WITH PROTEIN C DEFICIENCY
Martos, L.; (...); Espana, F.
Meeting Abstract. 10.1016/S0049-3848(14)50254-X. 2014
IDENTIFICATION OF A PLASMA MICRORNAS PROFILE INVOLVED IN VENOUS THROMBOSIS
Navarro, S.; (...); Espana, F.
Meeting Abstract. 10.1016/S0049-3848(14)50271-X. 2014
IDENTIFICATION OF A PROFILE OF CLASSES OF CIRCULATING LIPIDS ASSOCIATED WITH THE VENOUS THROMBOEMBOLISM
Fernandez-Pardo, A.; (...); Navarro, S.
Meeting Abstract. 2019
Immune Tolerance Induction in A Patient with Severe Haemophilia A and Factor VIII Inhibitors
Freiria Alberte, C.; (...); Haya Guaita, S.
Meeting Abstract. 2017
IMPACT OF INITIATION OF PROPHYLAXIS, SYNOVITIS AND FUNCTIONALITY ON JOINT HEALTH IN PATIENTS WITH HEMOPHILIA
Chimeno, A.; (...); Bonanad Boix, S.
Meeting Abstract. 2023
Increase of Neutrophil Activation Markers in Venous Thrombosis-Contribution of Circulating Activated Protein C
Martos L; (...); Medina P
Article. 10.3390/ijms21165651. 2020
Increased circulating dna, calprotectin and mieloperoxidase, as neutrophil extracellular trap markers, are risk factors for deep vein thrombosis
Martos, L.; (...); Medina, P.
Meeting Abstract. 2015
INCREASED LEVELS OF FREE CIRCULATING DNA AND DNASE 1 ACTIVITY IN PLASMA IS ASSOCIATED WITH AN INCREASED RISK OF VENOUS THROMBOEMBOLISM
Oto, J.; (...); Medina, P.
Meeting Abstract. 2019
Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Vericat, JEM; (...); Bonanad, S
Meeting Abstract. 2018
Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables
Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago
Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016
Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A
Article. 10.1111/hae.12439. 2014
Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score.
Jiménez-Yuste V; (...); Kim HK
Article. 10.1111/hae.13628. 2019
Management of acquired hemophilia A: results from the Spanish registry.
Mingot-Castellano ME; (...); Marco P
Article. 10.1182/bloodadvances.2021004626. 2021
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab.
Jiménez-Yuste V; (...); Rodríguez-López M
Article. 10.1055/s-0044-1785525. 2024
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.
Rodríguez MA; (...); Chimeno-Hernández A
Article. 10.1016/j.thromres.2024.109181. 2024
Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds
Andersson, NG; (...); PedNet Haemophilia Res Fdn
Article. 10.3324/haematol.2018.209619. 2019
Moderate and severe haemophilia in Spain: An epidemiological update
Aznar, JA; (...); Lopez, MF
Letter. 10.1111/hae.13462. 2018
Moderate haemophilia A: Recommendations from a Spanish panel of experts.
Álvarez Román MT; (...); López-Jaime FJ
Article. 10.1111/hae.15110. 2024
Modification of a thrombin generation test to identify new cofactors of the protein C pathway in plasma
Martos, L.; (...); Navarro, S.
Meeting Abstract. 2015
Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients
Borràs N; (...); Corrales, I
Article. 10.3324/haematol.2017.168765. 2017
Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm
Batlle J; (...); Vidal F
Article. 10.1160/TH15-04-0282. 2016
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
Monitoring drug activity of dabigatran and rivaroxaban by thrombin generation using the calibrated automated thrombinoscope
Moret, A.; (...); Bonanad, S.
Meeting Abstract. 2015
MONITORING OF THE JOINT HEALTH OF PATIENTS WITH HEMOPHILIA IN SPAIN. INITIAL ANALYSIS OF THE JOINT US PROJECT
Alvarez-Roman, MT; (...); Querol, F
Meeting Abstract. 2021
Mortality caused by intracranial bleeding in non-severe hemophilia A patients
Loomans, JI; (...); Fijnvandraat, K
Article. 10.1111/jth.13693. 2017
Multimodal exercises program to improve balance in patients with haemophilia: preliminary results
Chimeno-Hernandez, A; (...); Quero, F
Meeting Abstract. 2021
Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score
Falantes J; (...); Sanz G
Article. 10.1016/j.leukres.2014.10.004. 2015
Muscle strength in load-bearing joints in haemophilic patients: comparative values with the general population
Bonanad-Boix, S.; (...); Querol, F.
Meeting Abstract. 2015
Muscle Strength in Spanish Children with Mild and Severe Haemophilia A
Bonanad, S.; (...); Querol-Fuentes, F.
Meeting Abstract. 2016
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Neutrophil extracellular traps (NETs) in patients with STEMI. Association with percutaneous coronary intervention and antithrombotic treatments.
Ferre-Vallverdu, Mari; (...); Moscardo, Antonio
Article. 10.1016/j.thromres.2022.03.002. 2022
Next generation sequencing in bleeding disorders: two novel variants in the F5 gene (Valencia-1 and Valencia-2) associated with mild factor V deficiency.
Moret, A; (...); Bonanad, S
Article. 10.1007/s11239-019-01911-z. 2019
Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development
Mannucci PM; (...); Klamroth R
Review. 10.1111/hae.12465. 2014
Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development (vol 20, pg 2, 2014)
Mannucci, P. M.; (...); Klamroth, R.
Correction. 10.1111/hae.12510. 2014
Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction
Lozano ML; (...); Rivera J
Article. 10.1182/blood-2015-11-683102. 2016
Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice
Bonanad, S; (...); Poveda, JL
Meeting Abstract. 2018
Patient and treatment related factors and inhibitor development after 50 exposure days in patients with non-severe hemophilia A-preliminary data of a nested case-control study
Abdi, A; (...); INSIGHT Study Grp
Meeting Abstract. 2019
PATIENT WITH CONGENITAL AFIBRINOGENEMIA AND PERIPHERAL ARTERIAL THROMBOSIS. THERAPEUTIC ANTITHROMBOTIC MANAGEMENT BASED ON MONITORING
Moscardo, A.; (...); Valles, J.
Meeting Abstract. 10.1016/S0049-3848(14)50371-4. 2014
Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Pegcetacoplan: Real Life Experience
Vallejo, Carlos; (...); Vara, Miriam
Meeting Abstract. 10.1182/blood-2023-185570. 2023
Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products.
Megias-Vericat, J. E.; (...); Poveda Andres, J. L.
Article. 10.1016/j.thromres.2022.06.001. 2022
Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery
Peyvandi, F; (...); Sytkowski, A
Article. 10.1111/jth.14313. 2019
Physical Activity in adult patient with haemophilic arthropathy monitored by Fitbit Charge HR
Perez-Alenda, Sofia; (...); Bonanad, Santiago
Meeting Abstract. 2016
Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)
Querol-Fuentes, F; (...); Bonanad, S
Meeting Abstract. 2017
Physical Activity Monitoring and Acceptance of a Commercial Activity Tracker in Adult Patients with Haemophilia.
Carrasco JJ; (...); Querol F
Article. 10.3390/ijerph16203851. 2019
Pilot evaluation of home delivery programme in haemophilia
Megias-Vericat, JE; (...); Poveda-Andres, JL
Article. 10.1111/jcpt.12718. 2018
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
PK-guided switch from standard half-life to extended half-life factor VIII products
Megias-Vericat, JE; (...); Iorio, Alfonso
Meeting Abstract. 2020
Platelet function in malignant hematological disorders
Moscardó A; (...); Vallés J
Review. 10.1097/CCO.0000000000000237. 2015
Practical guide to emergency treatment of thrombotic microangiopathy
Romero S; (...); Grupo de Microangiopatía Trombótica del Hospital Universitario y Politécnico La
Editorial Material. 10.1016/j.medcli.2018.01.013. 2018
Predictive factors of immune tolerance treatment response in severe haemophilia A patients with inhibitors: A real-world report from a single centre, mixed retrospective-prospective long-term study
Haya, S; (...); Casana, P
Letter. 10.1111/hae.13660. 2019
Predictive models of treatment benefit in patients with autoimmune hepatitis and decompensated cirrhosis at diagnosis
Arvaniti, Pinelopi; (...); Carlota Londono, Maria
Meeting Abstract. 2023
Prophylactic treatment in hemophilic patients with inhibitors.
Article. 10.1097/MBC.0000000000000823. 2019
PROPOSAL FOR A MULTIMODAL BALANCE EXERCISE PROGRAM FOR PEOPLE WITH HAEMOPHILIA
Chimeno-Hernandez, A; (...); Bonanad, S
Meeting Abstract. 2020
Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings
Parra Lopez R; (...); Rendo P
Article. 10.1160/TH14-09-0760. 2015
Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary.
Tiede A; (...); Oldenburg J
Article. 10.1111/hae.14178. 2020
Quality of thawed plasma inactivated with methylene blue after 48-hour storage
Balaguer A; (...); Sanz MÁ
Letter. 10.1016/j.transci.2014.11.005. 2015
Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker
Perez-Alenda, S; (...); Querol, F
Letter. 10.1111/hae.13388. 2018
Radiosynoviorthesis in the Treatment of Recurrent Hemarthrosis in Patients with Haemophilia: Experience in a Single Center
Querol-Fuentes, F; (...); Bonanad, S
Meeting Abstract. 2017
Real World Bleeding Frequency in Patients with Inhibitors on Prophylaxis with Feiba: First Data Read-Out Of Feiba Global Outcome Study (FEIBA GO)
Escuriola-Ettingshausen, C; (...); Crea, R
Meeting Abstract. 2017
Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa.
Megias-Vericata, J. E.; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2023.11.023. 2023
Real-world bleeding frequency in inhibitor patients on prophylaxis with apcc: data read-out of the "feiba global outcomes study (FEIBA GO)"
Ettingshausen, CE; (...); Crea, R
Meeting Abstract. 2018
Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with > 18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)
Windyga, Jerzy; (...); Escuriola, Carmen
Meeting Abstract. 10.1182/blood-2019-124324. 2019
Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study.
Ettingshausen CE; (...); Windyga J
Article. 10.1177/20406207231184323. 2023
REAL-WORLD EFFICACY AND SAFETY DATA OF PATIENTS WITH HEMOPHILIA AND INHIBITORS TREATED WITH APCC: "FEIBA GLOBAL OUTCOME STUDY (FEIBA-GO)", RESULTS FROM > 12 MONTHS FOLLOW-UP
Windyga, J; (...); Escuriola-Ettinghausen, C
Meeting Abstract. 2019
Remote monitorization of physical exercises for patients with hemophilia using kinect V2
Perez-Alenda, S; (...); Querol-Fuentes, F
Meeting Abstract. 2018
RETROSPECTIVE STUDY OF AZACITIDINE IN PATIENTS OF ADVANCED AGE WITH ACUTE MYELOID LEUKEMIA (LMA). RESULTS OF THE ALMA/ PETHEMA COHORT IN COMPARISON WITH THE MRC RISK INDEX SCORE
Falantes, J.; (...); Ramos, F.
Meeting Abstract. 2015
RFVIIIFC FOR FIRST-TIME IMMUNE TOLERANCE INDUCTION (ITI) THERAPY: INTERIM RESULTS FROM THE GLOBAL, PROSPECTIVE VERITI-8 STUDY
Malec, L; (...); Peyvandi, F
Meeting Abstract. 2019
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors
Mancuso, ME; (...); European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal
Article. 10.1160/TH17-01-0059. 2017
Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project
Perez-Rodriguez, A; (...); Lopez-Fernandez, MF
Article. 10.1371/journal.pone.0197876. 2018
Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
Chelle, P; (...); Edginton, A
Meeting Abstract. 2018
Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients.
Chelle P; (...); Edginton A
Article. 10.1007/s10928-019-09637-4. 2019
Safety and Effectiveness of Progressive Moderate-to-Vigorous Intensity Elastic Resistance Training on Physical Function and Pain in People With Hemophilia.
Calatayud J; (...); Casaña J
Article. 10.1093/ptj/pzaa106. 2020
Signal transducer and activator of transcription 3 (STAT3) phosphorylation regulates thromboxane A 2 receptor activity in human platelets.
Latorre AM; (...); Moscardó A
Letter. 10.1111/bjh.16309. 2020
Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study
Peyvandi, Flora; (...); Frits, Rosendaal R.
Meeting Abstract. 2015
Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors
Mingot-Castellano, ME; (...); Sedano-Balbas, C
Review. 10.1111/ejh.12730. 2016
Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors
Lopez-Fernandez, MF; (...); Balbas, CS
Article. 10.1160/TH15-07-0568. 2016
Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
Villegas A; (...); Urbano-Ispizua Á
Editorial Material. 10.1016/j.medcli.2015.12.012. 2016
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.
Pinana, JL; (...); Bosch F
Article. 10.1080/10428194.2021.1992619. 2021
Study of The Correlation Between Osteoporosis and Arthropathy in Haemophilia Patients Using Self-Organizing Maps
Querol-Fuentes, F.; (...); Bonanad, S.
Meeting Abstract. 2015
Suitability and readiness assessment of organizational resources for the implementation of gene therapy in hemophilia in Spain and Portugal: A survey-based study.
Villas JMC; (...); Álvarez-Román MT
Letter. 10.1016/j.thromres.2024.109180. 2024
SWITCH ANALYSIS GUIDED BY PHARMACOKINETICS FROM FACTORS VIII OF STANDARD HALF LIFE TO EXTENDED HALF LIFE FACTORS
Megias Vericat, J. E.; (...); Poveda, A. J. L.
Meeting Abstract. 2019
Synoviorthesis in the Treatment of Recurrent Hemarthrosis in Haemophilia Patients with Inhibitors
Querol-Giner, M.; (...); Querol-Fuentes, F.
Meeting Abstract. 2016
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
Carcao, M; (...); Future Immunotolerance Treatment
Article. 10.1111/hae.13762. 2019
The factor VIII treatment history of non-severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEAD-US system
Roman, MTA; (...); Mosteirin, NF
Letter. 10.1111/jth.15475. 2021
The impact of progressive resistance training on physical function and quality of life in patients with haemophilia
Carrasco, JJ; (...); Querol-Fuentes, F
Meeting Abstract. 2019
The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
Gresele, P; (...); BAT-VAL Study Investigators
Article. 10.1111/jth.15263. 2021
The Limitations and Unmet Needs of the Five Cornerstones to Guarantee Lifelong Optimization of Prophylaxis in Hemophilia Patients.
Nunez, Ramiro; (...); Jimenez-Yuste, Victor
Article. 10.1055/s-0042-1757745. 2022
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.
Escobar, M; (...); Kessler, C
Article. 10.1111/hae.14419. 2021
THROMBIN GENERATION TEST IN PATIENTS UNDER NEW ORAL ANTICOAGULANTS (DABIGATRAN AND RIVAROXABAN)
Cabrera, N.; (...); Bonanad, S.
Meeting Abstract. 10.1016/S0049-3848(14)50148-X. 2014
Thromboembolic hazard in hereditary hemorrhagic telangiectasia.
Asensi Canto, Pedro; (...); Bonanad Boix, Santiago
Article. 10.1002/jha2.471. 2022
Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study.
Bravo-Perez, Carlos; (...); Corral, Javier
Article. 10.1016/S2352-3026(24)00138-8. 2024
Tolerability of knee and ankle exercises with machines and elastic resistance in patients with severe hemophilia
Perez-Alenda, S; (...); Bonanad, S
Meeting Abstract. 2018
Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project
Perez-Rodriguez, Almudena; (...); Lopez-Fernandez, Maria Fernanda
Article. 10.1111/hae.14405. 2021
Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD-US system.
Jiménez-Yuste V; (...); Kim HK
Article. 10.1111/hae.14280. 2021
Ultrasound Protocol for the Diagnosis and Monitoring of the Acute Hemarthrosis
Querol-Fuentes, F.; (...); Bonanad, S.
Meeting Abstract. 2016
Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA
Borras, N; (...); Corrales, I
Article. 10.3324/haematol.2018.203166. 2019
Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort
Borras, N; (...); Vidal, F
Article. 10.1055/s-0040-1702227. 2020
Until what age should we worry about inhibitors? New data from the PedNet Registry on 1,038 PUPs with severe hemophilia a followed from the first until over 1,000 exposure days
van den Berg, M; (...); PedNet Study Grp
Meeting Abstract. 2019
Update on Molecular Testing in von Willebrand Disease
Batlle, J; (...); PCM-EVW-ES Investigators Team
Review. 10.1055/s-0039-1679922. 2019
Upper-Body Exercises With External Resistance Are Well Tolerated and Enhance Muscle Activity in People With Hemophilia
Calatayud, J; (...); Casana, J
Article. 10.1093/ptj/pzy136. 2019
Usability and usefulness of a wearable activity tracker in patients with hemophilia
Querol-Fuentes, F; (...); Bonanad, S
Meeting Abstract. 2018
Usefulness of short-term peripheral ambulatory ultrafiltration in heart failure refractory to diuretics. Initial experience.
Guerrero Cervera B; (...); Almenar Bonet L
Article. 10.1016/j.medcli.2023.04.008. 2023
Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC.
Gresele P; (...); BAT-VAL study investigators
Article. 10.1111/jth.14683. 2020
Validity of a depth camera for elbow range of motion measurement in haemophilic patients: The first step for a telemedicine approach
Mateo, F; (...); Querol-Fuentes, F
Meeting Abstract. 2018
Variation in baseline factor VIII concentration in a retrospective cohort of mild/moderate hemophilia A patients carrying identical F8 mutations
Loomans, JI; (...); Fijnvandraat, K
Article. 10.1111/jth.13581. 2017